159 related articles for article (PubMed ID: 36620588)
21. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
Cagnin S; Donghia R; Martini A; Pesole PL; Coletta S; Shahini E; Boninsegna G; Biasiolo A; Pontisso P; Giannelli G
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003675
[TBL] [Abstract][Full Text] [Related]
22. A Statistical Approach to the Diagnosis and Prediction of HCC Using CK19 and Glypican 3 Biomarkers.
Burciu C; Șirli R; Bende R; Popa A; Vuletici D; Miuțescu B; Rațiu I; Popescu A; Sporea I; Dănilă M
Diagnostics (Basel); 2023 Mar; 13(7):. PubMed ID: 37046471
[TBL] [Abstract][Full Text] [Related]
23. GALAD score and a proposal for GALADUS model for detecting hepatocellular carcinoma in Vietnamese patients with chronic liver disease.
Phuong PC; Khoa MT; Loi NT; Quynh VTT; Luan ND; Mai NTH; Dung NV; Hung NQ; Lieu DQ; Nam LV; Tra DT; Thai PV; Duc NM
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1111-1122. PubMed ID: 38375717
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of the GALAD model for diagnosing primary hepatocellular carcinoma.
Lu JL; Yuan XY; Zhang JS; Li Y
Technol Health Care; 2024 May; ():. PubMed ID: 38759033
[TBL] [Abstract][Full Text] [Related]
25. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
[TBL] [Abstract][Full Text] [Related]
26. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.
Lin N; Lin Y; Xu J; Liu D; Li D; Meng H; Gallant MA; Kubota N; Roy D; Li JS; Gorospe EC; Sherman M; Gish RG; Abou-Alfa GK; Nguyen MH; Taggart DJ; Van Etten RA; Hoshida Y; Li W
Hepatol Commun; 2022 Jul; 6(7):1753-1763. PubMed ID: 35244350
[TBL] [Abstract][Full Text] [Related]
27. Risks and Clinical Predictors of Hepatocellular Carcinoma in Chinese Populations: A Real-World Study of 10,359 Patients in Six Medical Centers.
Huang C; Xiao X; Tong L; Gao Z; Ji J; Zhou L; Li Y; Liu L; Feng H; Fang M; Gao C
J Hepatocell Carcinoma; 2024; 11():411-425. PubMed ID: 38435681
[TBL] [Abstract][Full Text] [Related]
28. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
Yang JD; Addissie BD; Mara KC; Harmsen WS; Dai J; Zhang N; Wongjarupong N; Ali HM; Ali HA; Hassan FA; Lavu S; Cvinar JL; Giama NH; Moser CD; Miyabe K; Allotey LK; Algeciras-Schimnich A; Theobald JP; Ward MM; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Srivastava S; Rinaudo JA; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):531-538. PubMed ID: 30464023
[TBL] [Abstract][Full Text] [Related]
29. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
30. Validation of the hepatocellular carcinoma early detection screening algorithm Doylestown and aMAP in a cohort of Chinese with cirrhosis.
Qian Y; Li L; Ma L; Ji R; Ying S; Zhou J; Fu L; Yang G
J Clin Lab Anal; 2022 Apr; 36(4):e24296. PubMed ID: 35218083
[TBL] [Abstract][Full Text] [Related]
31. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.
Toyoda H; Kikuchi K; Tsuruta Y; Hiraoka A; Tsuji K; Tanaka J
Nephrol Dial Transplant; 2021 May; 36(6):1097-1103. PubMed ID: 33009910
[TBL] [Abstract][Full Text] [Related]
32. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
El-Serag HB; Jin Q; Nabihah T; Salem E; Luster M; Alsarraj A; Khaderi S; Singal AG; Marrero JA; Asrani SK; Kanwal F
Hepatology; 2024 Jun; ():. PubMed ID: 38899967
[TBL] [Abstract][Full Text] [Related]
33. Serologic Detection of Hepatocellular Carcinoma: Application of Machine Learning and Implications for Diagnostic Models.
Johnson PJ; Bhatti E; Toyoda H; He S
JCO Clin Cancer Inform; 2024 Mar; 8():e2300199. PubMed ID: 38513163
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.
Hu B; Tian X; Sun J; Meng X
Int J Mol Sci; 2013 Dec; 14(12):23559-80. PubMed ID: 24317431
[TBL] [Abstract][Full Text] [Related]
35. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
36. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds.
Song T; Wang L; Xin R; Zhang L; Tian Y
J Int Med Res; 2020 Oct; 48(10):300060520969087. PubMed ID: 33135527
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
Volk ML; Hernandez JC; Su GL; Lok AS; Marrero JA
Cancer Biomark; 2007; 3(2):79-87. PubMed ID: 17522429
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
